[Clinical study of cefminox in XXXX ].

@entity1 @entity3617 @entity796 @entity55 @entity327 @entity794 @entity4595 @entity11294 @entity1729 @entity4005 @entity7407 @entity7749
A new cephem cefminox (CMNX, @entity7407 ) was used in the treatment of 22 cases of @entity1729 without taking into account background factors of @entity1 . The dosage was 2 to 4 g/day in 2 divided doses and the treatment was continued for a period 2 to 17 days. The breakdown of the diseases treated was; @entity55 in 7 cases, secondary lung abscess (rS3)+ @entity11294 in 1 case, chronic @entity3617 in 3 cases, @entity4595 in 10 cases and @entity7749 (suspected) in 1 case. The clinical results were rated as excellent in 7 cases, good in 11 cases, fair in 1 case and unknown in 3 cases, with an excellent rate of 36.8% and excellent+good rate of 94.7%. The causative organisms were identified in 10 cases and included @entity327 for 8 cases, @entity4005 sp. for 1 case and @entity794 for 1 case. The analysis of bacteriological study revealed disappearance of all of these organisms. However, in 3 out of 8 cases where @entity327 was isolated and in 1 case where @entity4005 sp. was isolated the changes of organisms to @entity796 were observed. As the adverse reactions, rashes developed in 1 case and moreover laboratory test results revealed elevation in transaminase in 3 cases. All of these symptoms were mild in nature and none of our cases experienced serious adverse reactions attributable to CMNX. From these results, we believe that CMNX is one of the useful drugs for the treatment of @entity1729 .
